Practical considerations on current guidelines for the management of non-neutropenic adult patients with candidaemia

Mycoses

Volumn 56, Issue 1, 2013, Pages 11-20

  Glockner A ^a   Cornely, O A ^b  

^a BDH Klinik Greifswald   (Germany)

^b University of Cologne   (Germany)

Author keywords

Azole; Candidaemia; Echinocandin; Guideline; Treatment

Indexed keywords

ANIDULAFUNGIN; ECHINOCANDIN; FLUCONAZOLE; PYRROLE DERIVATIVE;

ANTIFUNGAL SUSCEPTIBILITY; BLOOD CULTURE; CANDIDA; CANDIDEMIA; CENTRAL VENOUS CATHETER; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; ANTIFUNGAL AGENTS; CANDIDEMIA; CATHETERIZATION, CENTRAL VENOUS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT FAILURE;

CANDIDA;

EID: 84871615766     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02208.x     Document Type: Review

References (57)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5.
3. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-5.
4. Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF. Candidemia in intensive care unit patients: risk factors for mortality. Infection 1997; 25: 8-11.
5. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
6. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
7. Guzman JA, Tchokonte R, Sobel JD. Septic shock due to candidemia: outcomes and predictors of shock development. J Clin Med Res 2011; 3: 65-71.
8. Allou N, Allyn J, Montravers P. When and how to cover for fungal infections in patients with severe sepsis and septic shock. Curr Infect Dis Rep 2011; 13: 426-32.
9. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35.
10. Herbrecht R, Flückinger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Antifungal therapy in leukemia patients guidelines update ECIL-4. http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/ECIL%204Update%202011%20Antifungal%20therapy.pdf [accessed on 2 May 2012].
11. Ullmann AJ, Cuenca-Estrella M, Lortholary O, Cornely OA, Roilides E. Presentation of the ESCMID diagnostic and management guidelines for Candida diseases 2011. Educational workshop EW 16; ECCMID 2011.
12. Ruhnke M, Rickerts V, Cornely OA et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011; 54: 279-310.
13. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
14. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
15. Kumar A, Skrobik I, Guzman J et al. The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. ICAAC 2007; abstract K-2174.
16. Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 2009; 16: 508-11.
17. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-90.
18. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
19. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
20. Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole therapy incritically ill patients. ISICEM 2010; Poster A75.
21. Mann PA, McNicholas PM, Chau AS et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009; 53: 5026-34.
22. Lortholary O, Desnos-Ollivier M, Sitbon K et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2, 441 patients. Antimicrob Agents Chemother 2011; 55: 532-8.
23. Glöckner A, Abel P, Bernhardt H, Zimmermann K, Wiersbitzly M. Mycological findings upon Admission to A non-surgical ICU. ICAAC 2002; Poster M-874.
24. Oxman DA, Chow JK, Frendl G et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010; 65: 1460-5.
25. Paiva JA, Ruhnke M, Meersseman W. Anidulafungin for treatment of candidemia/invasive candidiasis in selected intensive care unit populations. SCCM Annual Meeting 2010; Abstract 297.
26. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn Microbiol Infect Dis 2010; 68: 278-83.
27. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011; 38: 65-9.
28. Tortorano AM, Dho G, Prigitano A et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). Mycoses 2012; 55: 73-9.
29. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125(1 Suppl): S3-13.
30. Arendrup MC. Susceptibility breakpoints and resistance to antifungals among Candida species - where are we in 2011? ECCMID 2011; presentation S428.
31. European Commitee on Antimicrobial Susceptibility Testing. Antimicrobials for Candida infections - EUCAST clinical MIC breakpoints v.3.0 2011-04-27. http://www.srga.org/eucastwt/MICTAB/EUCASTclinicalMICbreakpoints-antimicrobialsforCandida infections.htm [accessed on 2 May 2012].
32. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-76.
33. Estivill D, Arias A, Torres-Lana A, Carrillo-Muñoz AJ, Arévalo MP. Biofilm formation by five species of Candida on three clinical materials. J Microbiol Methods 2011; 86: 238-42.
34. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
35. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-67.
36. Andes DR, Safdar N, Baddley J et al. Impact Of Therapy On Mortality Across Candida spp In Patients With Invasive Candidiasis From Randomized Clinical Trials: A Patient Level Analysis. Presentation M-1312; 50th ICAAC, Boston, MA, USA, September 11-15, 2010.
37. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36: 2967-72.
38. Asmundsdóttir LR, Erlendsdóttir H, Gottfredsson M. Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland. Scand J Infect Dis 2005; 37: 111-20.
39. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20: 571.
40. Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21: 994-6.
41. Nucci M, Silveira MI, Spector N et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998; 27: 107-11.
42. Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007; 13: 788-93.
43. Velasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27: 1071-8.
44. Weinberger M, Leibovici L, Perez S et al. Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 2005; 61: 146-54.
45. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51: 295-303.
46. DiDone L, Oga D, Krysan DJ. A novel assay of biofilm antifungal activity reveals that amphotericin B and caspofungin lyse Candida albicans cells in biofilms. Yeast 2011; 28: 561-8.
47. Fiori B, Posteraro B, Torelli R et al. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob Agents Chemother 2011; 55: 3031-5.
48. Kucharíková S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. Antimicrob Agents Chemother 2010; 54: 4474-5.
49. Seidler M, Salvenmoser S, Müller FM. Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model. FEMS Yeast Res. 2010; 10: 492-5. Epub 2010 Mar 5.
50. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
51. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
52. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-42.
53. Davis S, Kouza A, Wiegand T, Vazquez J Conversion of intravenous echinocandins to oral azoles for invasive candidiasis: impact on outcomes and resource utilisation. ECCMID 2008; Abstract O458.
54. Analysis of data from the randomized trial of anidulafungin vs. fluconazole for invasive candidiasis (Reboli et al. [19]; Pfizer data on file).
55. ®) summary of product characteristics; August 2011.
56. ®) summary of product characteristics; July 2011.
57. ®) summary of product characteristics; November 2010.